|
is a Japanese pharmaceutical company, subsidiary of Otsuka Holdings. The company focuses on developing cancer treatments. Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. Taiho is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Taiho is the Japanese second-largest by prescription oral oncology sales. The company mainly covers oncology related therapeutic area: stomach cancer, colorectal cancer, pancreatic cancer, breast cancer and more. Taiho engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Taiho is a full member of the Japan Pharmaceutical Manufacturers Association (JPMA). In March 2013, Taiho has over 2,500 employees worldwide and achieved $1.3 billion USD in revenue during the 2012 fiscal year. http://www.taiho.co.jp/english/corporation/highlights.html *$1,329,817 (Note: U.S. dollar amounts are translated from yen, for convenience only, at the rate of ¥94=US$1, the approximate exchange rate at March 31, 2013) ==History== 1963 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Taiho Pharmaceutical」の詳細全文を読む スポンサード リンク
|